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2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) is a widespread environmental con-
taminant (Zook and Rappe 1994) and
known endocrine disruptor (Birnbaum and
Tuomisto 2000). In animal studies, signifi-
cant effects on ovarian function and steroid
levels have been reported with both in utero
and postnatal TCDD exposure. Studies in
rats and monkeys suggest that TCDD may
affect ovarian function directly or indirectly
via the pituitary (Gao et al. 2000; Li et al.
1995b; Moran et al. 2001, 2002). 
In utero and lactational TCDD exposure
in rats has been associated with reduced ovar-
ian weight and decreased numbers of corpora
lutea and pre-antral and antral follicles (Flaws
et al. 1997; Gray and Ostby 1995; Heimler
et al. 1998). Postnatal TCDD exposure in rats
has been associated with reduced ovarian
weight gain, ovulation rate, and numbers of
corpora lutea and follicles, as well as inhibition
of follicular rupture, morphologic changes in
the ovary, and altered cyclicity with disruption
of the estrous cycle (Gao et al. 1999; Kociba
et al. 1976; Li et al. 1995a, 1995b; Roby
2000, 2001; Salisbury and Marcinkiewicz
2002; Silbergeld and Mattison 1987; Son
et al. 1999; Umbreit et al. 1987). Although
TCDD does not increase apoptosis of follicles
(Heimler et al. 1998), it appears to slow follic-
ular maturation (Mattison 1980; Silbergeld
and Mattison 1987; Son et al. 1999).
Alterations in steroid levels have also been
noted with TCDD exposure. In utero and lac-
tational exposure in rats was associated with
decreased estradiol (Chaffin et al. 1996). In
rats, increased estradiol, reduced follicle stim-
ulating hormone (FSH) and luteinizing hor-
mone, and no change in progesterone were
found during pro-estrous (Gao et al. 1999;
Li et al. 1995a). Similar outcomes have been
reported in primates, including decreases in
estradiol and progesterone (Allen et al. 1979;
Barsotti et al. 1979; Guo et al. 1999; Moran
et al. 2001). In human luteinizing granulosa
cells, TCDD decreased estradiol (Enan et al.
1996), but did not alter progesterone produc-
tion (Moran et al. 2000). The above evidence
suggests that TCDD could alter human ovar-
ian function, including steroidogenesis and
ovulation.
In a case report, a woman with extremely
high serum TCDD (144,000 ppt) had amen-
orrhea and decreased serum estradiol and
progesterone levels (Geusau et al. 2001). To
our knowledge, no epidemiologic studies have
examined the potential effects of TCDD expo-
sure on quality of human ovarian function.
On 10 July 1976, as a result of a chemical
explosion, residents of Seveso, Italy, experi-
enced the highest levels of TCDD exposure
known in a residential population (Mocarelli
et al. 1988). Twenty years later, we initiated
the Seveso Women’s Health Study (SWHS)
to examine the relation of TCDD levels in
serum collected soon after the explosion with
reproductive health. We previously reported
that serum TCDD levels were associated with
an increase in risk for earlier menarche [haz-
ard ratio = 1.2; 95% conﬁdence interval (CI),
0.98 to 1.6] among women who were < 5
years of age at the time of the explosion
(Warner and Eskenazi 2005), an average
increase in menstrual cycle length of almost a
full day but only among those who were pre-
menarcheal at exposure (Eskenazi et al.
2002), and a nonmonotonic dose-related
association with earlier onset of natural
menopause up to a TCDD level of 100 ppt,
but not above (Eskenazi et al. 2005). In the
present study, we examined the relationship
of serum TCDD levels measured in serum
collected near the explosion with quality of
ovarian function, including ovarian follicles,
functional ovarian cysts, ovulation rate, and
serum hormone levels. 
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BACKGROUND: Although 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been associated with
alterations in ovarian function and hormones in animals, it has not been studied in humans. On
10 July 1976, an explosion exposed residents of Seveso, Italy, to the highest levels of TCDD in a
population. Twenty years later, we initiated the Seveso Women’s Health Study to study reproduc-
tive health. 
OBJECTIVE: We related TCDD levels measured in sera collected near the time of explosion and
ovarian function (ovarian cysts, ovarian follicles, ovulation rate, serum hormones) at follow-up.
METHODS: We included 363 women who were 20–40 years of age and nonusers of oral contracep-
tives. We examined the relationship of 1976 serum TCDD levels with ultrasound-detected ovarian
follicles among 96 women in the menstrual follicular phase and serum hormone levels (estradiol,
progesterone) among 129 women in the menstrual luteal phase at follow-up. Ovulation was deﬁned
by serum progesterone levels > 3 ng/mL. 
RESULTS: The median serum TCDD level was 77.3 ppt, lipid-adjusted. Serum TCDD was not
associated with number or size of ovarian follicles. Of women in the luteal phase, 87 (67%) ovu-
lated. Serum log10TCDD was not associated with odds of ovulation [adjusted odds ratio = 0.99;
95% conﬁdence interval (CI), 0.5 to 1.9]. Among those who had ovulated, serum log10TCDD was
not associated with serum progesterone [adjusted beta (adj-β) = –0.70; 95% CI, –2.4 to 1.0] or
estradiol (adj-β = –1.81; 95% CI, –10.4 to 6.8). 
CONCLUSIONS: We found no clear evidence that 1976 TCDD exposure was associated with ovarian
function 20 years later in women exposed to relatively high levels in Seveso, Italy. 
KEY WORDS: endocrine disruptor, hormones, ovary, TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
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Study population. The SWHS is the ﬁrst com-
prehensive epidemiologic study of the repro-
ductive health of a female population exposed
to TCDD. Women eligible for SWHS were
1 month to 40 years of age in 1976, had
resided in one of the most highly contaminated
areas based on surface soil TCDD levels (Zone
A or B), and had adequate stored sera collected
soon after the explosion (Eskenazi et al. 2000).
Recruitment took place from March 1996
through July 1998. Of 1,271 eligible women,
17 could not be contacted, and 33 had died or
were too ill to participate. Of the 1,221
women contacted, 981 (80%) agreed to partic-
ipate. Eligible for the quality of ovarian func-
tion analysis were 363 women who were
20–40 years of age and not using oral contra-
ceptives at follow-up. The functional ovarian
cyst analysis included the 310 women who
underwent ultrasound. The ovarian follicle
analysis was limited to the 96 women who
were in the pre-ovulatory window of the follic-
ular phase of the menstrual cycle (determined
by subtracting 14–18 days from self-report of
usual cycle length and date of last menstrual
period) at the time of ultrasound. The hor-
mone analysis was limited to the 129 women
in the luteal phase (last 14 days) of their men-
strual cycle at the time of the blood draw,
based on self-report of usual cycle length and
date of last menstrual period. 
Procedure. This study was approved by the
institutional review boards of the participating
institutions. Details of the study are presented
elsewhere (Eskenazi et al. 2000). Brieﬂy, after
participants gave written informed consent,
they underwent a fasting blood draw and were
interviewed by a trained nurse-interviewer who
was blinded to TCDD level and residence of
the woman. Information was collected during
the interview about demographic characteris-
tics, personal habits, and occupational, men-
strual, reproductive, and medical histories.
Medical records were requested for all gyneco-
logic treatments or conditions. After the inter-
view, women who were ≤ 50 years of age at
interview and who were still menstruating were
invited to undergo a gynecologic examination
and transvaginal ultrasound, and to complete
a menstrual cycle diary for 3 months.
Gynecologists at the University of Milan,
Mangiagalli Hospital, and for a few cases at
the Hospital of Desio conducted the examina-
tions and ultrasounds. The ultrasounds were
recorded on videotape, ovaries were pho-
tographed, and a structured codeable data form
was completed at the time of the examination
of each ovary with the notation of specific
items such as ovarian cysts. The transvaginal
ultrasound videotapes were reviewed by a sec-
ond gynecologist (D.L.O.), the number of fol-
licles was counted, and the diameter of all
follicles > 10 mm was recorded.
Laboratory analyses. Serum TCDD
analysis. TCDD was measured in archived
sera by high-resolution gas chromatography/
high-resolution mass spectrometry methods
(Patterson et al. 1987). Values are reported on
a lipid-weight basis in parts per trillion (Akins
et al. 1989).
Details of serum sample selection are pre-
sented elsewhere (Eskenazi et al. 2000). For the
363 women eligible for this analysis, we meas-
ured TCDD in sera collected between 1976
and 1977 for 330 (90.9%) women; between
1978 and 1982 for 25 (6.9%) women; and
between 1996 and 1997 for 8 (2.2%) women
whose earlier samples had insufﬁcient volume.
For nondetectable values (n = 29), a serum
TCDD level equal to one-half the detection
limit was assigned (Hornung and Reed 1990).
For women with detectable post-1977 TCDD
measurements (≥ 10 ppt), the TCDD expo-
sure level was back-extrapolated to 1976 using
the first-order kinetic model (Pirkle et al.
1989) for women who were > 16 years of age
in 1976 (n = 2) or the Filser model (Kreuzer
et al. 1997) otherwise (n = 25). For women
with post-1977 TCDD measurements that
were detectable but < 10 ppt (n = 3), the meas-
ured value was used for analysis. The study
median serum sample weight was 0.65 g, and
the median limit of detection was 18.8 ppt,
lipid-adjusted. 
Serum hormone analyses. Serum estra-
diol and progesterone levels were measured in
blood collected at the time of interview for
129 women. We classified ovulation status
(yes/no as to whether she had ovulated) for
each woman based on a serum progesterone
level > 3 ng/mL. Serum hormone analyses
were performed at the Hospital of Desio.
Serum estradiol measurements were made in
duplicate using the microparticle enzyme
immunoassay (Abbott Axsym System; Abbott
Laboratory, Abbott Park, IL, USA), and
serum progesterone measurements were made
using the chemiluminescence immunoassay
(Advia Centaur System; Bayer, East Walpole,
MA, USA). 
Statistical analyses. Ovarian follicles and
functional ovarian cysts. For the ovarian folli-
cle analysis, we considered serum TCDD levels
both as a continuous (log10 TCDD) and a cat-
egorical variable. The lowest TCDD cut-point
was first set at ≤ 20.0 ppt, and then the
remainder was divided into two equal size
groups (20.1–100, > 100 ppt). We selected
20 ppt (body burden ≈ 4 ng/kg) as the cut-
point because this was the average TCDD level
of 1976 serum pools collected from Italian
women living in an unexposed area (Eskenazi
et al. 2004). The prevalence of ovarian follicles
> 10 mm was considered a dichotomous out-
come (any/none). To evaluate the relationship
between serum TCDD and prevalence of ovar-
ian follicles, we performed logistic regression.
The total number of ovarian follicles, number
of ovarian follicles > 10 mm in diameter, and
diameter of dominant ovarian follicle were all
examined as continuous dependent variables
using multiple linear regression models. 
Covariates were considered for the multi-
variate regression analysis if they had been
reported in previous literature to be related to
ovarian follicles or functional cysts (Christensen
et al. 2002; Holt et al. 2003, 2005). We con-
sidered the following potential covariates: age
at ultrasound, age at explosion, age at menar-
che, menarche status at explosion, marital sta-
tus, parity, gravidity, age at last birth, lactation
history, current body mass index (BMI), smok-
ing, and education. We also considered effect
modiﬁcation by menarche status at explosion.
Covariates were kept in the multivariate model
if they were statistically signiﬁcant (p < 0.10).
For the functional ovarian cyst analysis,
the number of cases limited analyses to
descriptive statistics. 
Serum hormones and ovulation status.
For the serum hormone analysis, we consid-
ered serum TCDD levels both as a continuous
(log10TCDD) and a categorical variable.
Similar to the ovarian follicle analysis, the low-
est TCDD cut point was ﬁrst set at ≤ 20.0 ppt,
and then the remainder was divided into three
equal size groups (20.1–77.0, 77.1–212.0,
> 212 ppt). To evaluate the relationship
between serum TCDD and ovulation status,
we performed logistic regression. For the subset
of women whom we judged to have ovulated
(progesterone level > 3 ng/mL), serum estradiol
and progesterone levels were examined as a
continuous dependent variable using multiple
linear regression models. Analyses were per-
formed using STATA 8.0 (StataCorp., College
Station, TX, USA). All p-values are two-sided.
We considered covariates for the multivari-
ate analyses if they had been reported in previ-
ous literature to be related to ovulation status
or hormone levels (Windham et al. 2002). We
considered the following as potential covari-
ates: age at blood draw, age at explosion, age at
menarche, menarche status at explosion, mari-
tal status, parity, gravidity, history of abortion
(voluntary or spontaneous), mid-luteal phase at
time of blood draw, current BMI, smoking,
alcohol consumption, coffee consumption, tea
consumption, soda consumption, current
physical activity, and oral contraceptive use
(ever/never, total years, time since last use).
Covariates were kept in the multivariate model
if they were statistically signiﬁcant (p < 0.10).
We also considered effect modification by
menarche status at explosion.
Because square-root transformation
improved the normality of serum estradiol
slightly, linear regression models with estradiol
as the dependent variable were run with and
without square-root transformation. The
results were not different, so we report only
Serum dioxin and ovarian function
Environmental Health Perspectives • VOLUME 115 | NUMBER 3 | March 2007 337the untransformed results. All final models
were rerun excluding women who reported
stopping oral contraceptive use in the pre-
ceding 12 months (n = 11 for ovulation status,
n = 4 for serum hormones). Again, the results
were not different; therefore we report only
the full sample results.
Results 
Characteristics of the 363 women eligible for
the analysis are presented in Table 1. The
average age (± SD) at interview of the
363 women was 31.3 ± 5.3 years. All women
were Caucasian, 75% had ﬁnished more than
the required amount of education, 67% had
ever married, 17% were overweight or obese
(BMI > 25 kg/m2), 58% had ever used oral
contraceptives, 61% had never smoked, 88%
currently drank coffee, 53% were parous,
and 46% had reached menarche before the
explosion. Overall, the median lipid-adjusted
serum TCDD level for the 363 women was
77.3 ppt (interquartile range, 33–214 ppt;
range, 2.8–17,300 ppt). 
Ovarian follicles and functional ovarian
cysts. Of the 96 women in the pre-ovulatory
window of the follicular phase of their
menstrual cycle at the time of ultrasound,
94 (98%) had any follicles visualized in the
left and/or right ovary (mean ± SD = 9.5 ± 5.2
follicles; range, 1–24). Of these, 65 ± 67.7%
women had at least one follicle (range, 1–4)
> 10 mm in diameter. The median size of the
dominant follicle ranged from 10 to 28 mm
(median = 16 mm). The median lipid-adjusted
serum TCDD level for the 65 women with at
least one follicle > 10 mm was 80.5 ppt
(range, 4–2,730), nonsigniﬁcantly (p = 0.76)
lower than for the 31 women with no follicles
> 10 mm in diameter (median = 90.5 ppt;
range, 5.5–4,730).
As presented in Table 2, after controlling
for age and quality of ultrasound, a 10-fold
increase in TCDD (log10TCDD) was not
associated with odds of having any follicles
> 10 mm [adjusted odds ratio (AOR) = 0.99;
95% CI, 0.4 to 2.2; p = 0.99]. When serum
TCDD levels were categorized, compared
with the lowest exposure group, women were
more likely to have any follicles > 10 mm, but
not signiﬁcantly, and there was no evidence of
a dose response (test for trend: p = 0.92).
After adjusting for covariates, relative to
women with TCDD levels ≤ 20.0 ppt, the
odds of having any follicles > 10 mm among
women with TCDD levels from 20.1 to 100
ppt and > 100 ppt were 2.90 (95% CI, 0.8 to
10.8; p = 0.11) and 1.45 (95% CI, 0.4 to 5.5;
p = 0.59), respectively. 
In regression analysis, total number of
ovarian follicles was not related to serum
TCDD level. After adjusting for age and
quality of ultrasound, a 10-fold increase in
TCDD (log10TCDD) was not associated
with a change in total follicles [adjusted β
(adj-β) = 0.49; 95% CI, –1.1 to 2.1; p =
0.54]. When TCDD levels were categorized,
there was still no evidence of a dose response
with total follicles (test for trend: p = 0.80).
The size of the dominant follicle was also not
related to serum TCDD level either as a con-
tinuous (adj-β = 0.21; 95% CI, –2.9 to 3.4;
p = 0.89) or a categorical variable (p = 0.99). 
In total, 8 of 310 women had a functional
ovarian cyst (7 with follicular, 1 with luteal)
diagnosed at ultrasound. The median serum
TCDD levels for the 8 functional cyst cases
(median = 82.3 ppt) was only slightly higher
than noncases (n = 302, median = 78.0 ppt),
but not signiﬁcantly (p = 0.69). 
Serum hormones and ovulation. Of the
129 women who were in the luteal phase of
their menstrual cycle at blood draw, 87 (67%)
were classiﬁed as having ovulated (> 3 ng/mL
progesterone). Lipid-adjusted serum TCDD
levels for the 87 women who had ovulated
(median = 112.0 ppt) were not significantly
different from the levels of 42 women who had
not ovulated (median = 107.1 ppt) (p = 0.71). 
As presented in Table 3, after controlling
for age, mid-luteal phase, and oral contracep-
tive use in the preceding year, a 10-fold
increase in TCDD (log10TCDD) was not
associated with a reduced odds of ovulation
(AOR = 0.99; 95% CI, 0.5 to 1.9; p = 0.97).
When serum TCDD levels were categorized,
compared with the lowest exposure group,
women were less likely to ovulate, but not sig-
nificantly, and there was no evidence of a
dose response (test for trend: p = 0.93). After
adjusting for covariates, relative to women
with TCDD levels ≤ 20.0 ppt, the odds of
ovulation among women with TCDD levels
from 20.1 to 77.0 ppt, 77.1 to 212.0 ppt, and
> 212.0 ppt were 0.59 (95% CI, 0.1 to 2.5;
p = 0.48), 0.66 (95% CI, 0.2 to 2.8; p = 0.57),
and 0.73 (95% CI, 0.2 to 3.4; p = 0.69),
respectively. 
When we repeated the analysis in the sub-
set of 74 women who were in the mid-luteal
phase of their menstrual cycle at blood draw,
the results were similar (Table 3). After con-
trolling for age and oral contraceptive use in
the preceding year, log10TCDD was not asso-
ciated with a decreased odds of ovulation
(AOR = 1.03; 95% CI, 0.4 to 2.7; p = 0.96).
When serum TCDD levels were categorized,
there was still no evidence of a dose response
(test for trend: p = 0.95). After adjusting for
covariates, relative to women with TCDD
levels ≤ 20.0 ppt, the odds of ovulation among
women with TCDD levels from 20.1 to
77.0 ppt, 77.1 to 212.0 ppt, and > 212.0 ppt
were 0.71 (95% CI, 0.1 to 6.5; p = 0.76), 1.23
(95% CI, 0.1 to 10.9; p = 0.85), and 0.74
(95% CI, 0.1 to 7.1; p = 0.80), respectively.
Among the 87 women who were classiﬁed
as having ovulated, mean serum levels of
progesterone and estradiol were 11.0 ± 5.8
ng/mL and 78.4 ± 29.1 pg/mL, respectively.
Serum progesterone levels were significantly
higher among women in the mid-luteal phase
of their menstrual cycle at time of blood
draw, and both progesterone and estradiol
levels were lower among older women, but
not significantly. In regression analysis of
women who had ovulated (Table 4), after
controlling for age and mid-luteal phase, a
10-fold increase in TCDD (log10TCDD) was
not associated with serum progesterone (adj-β
= –0.70; 95% CI, –2.4 to 1.0; p = 0.42) or
serum estradiol (adj-β = –1.81; 95% CI,
–10.4 to 6.8; p = 0.68). As presented in Table
4, when serum TCDD levels were catego-
rized, compared with the lowest exposure
group, progesterone and estradiol levels both
were decreased, but not significantly, and
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Table 1. Select characteristics of the subsample of
363 women (≤ 40 years of age who were not cur-
rently on oral contraceptives), SWHS, 1996–1998.
Characteristic No. (%)
Total 363 (100)
Age at interview (years)
20–28 112 (30.9)
29–33 118 (32.5)
34–40 133 (36.6)
Education
≤ Required 93 (25.6)
Intermediate/professional 147 (40.5)
≥ High school 123 (33.9)
Married
Never 119 (32.8)
Ever 244  (67.2)
Current BMI
Underweight 32 (8.8)
Normal 268 (73.8)
Overweight 46 (12.7)
Obese 17 (4.7)
Oral contraceptive use
Never 152 (41.9)
Ever 211 (58.1)
Cigarette smoking
Never 223 (61.4)
Former 53 (14.6)
Current 87 (24.0)
Parity
0 171 (47.1)
1 88 (24.2)
≥ 2 104 (28.7)
Lactation history (months)
0 194 (53.4)
1–6 105  (28.9)
> 6  64 (17.6)
Menarche before explosion
No 195 (53.7)
Yes 168  (46.3)
Table 2. Adjusted odds ratio (AOR) and 95% CI for
any follicles with serum TCDD level among women
in the follicular phase (n = 96), SWHS, 1996–1998.
TCDD (ppt) Any/total (%) AORa (95% CI)
log TCDD 65/96 (67.7) 0.99 (0.4 to 2.2)
≤ 20.0 7/13 (53.8) 1.0
20.1–100 31/41 (75.6) 2.90 (0.8 to 10.8)
> 100 27/42 (64.3) 1.45 (0.4 to 5.5)
aAdjusted for age at ultrasound and quality of ultrasound.there was no evidence of a dose response for
either hormone (test for trend: progesterone
p=   0.51; estradiol p = 0.47). 
When we repeated the analysis in the
-subset of 55 women who had ovulated and
were in the mid-luteal phase of their men-
strual cycle at blood draw, the results were
similar (Table 4). After controlling for age,
log10TCDD was not associated with proges-
terone (adj-β = –0.84; 95% CI, –3.7 to 2.0;
p = 0.56) or estradiol (adj-β = –3.11; 95% CI,
–14.1 to 7.8; p = 0.57). When serum TCDD
levels were categorized, the decrease in proges-
terone and estradiol was larger, but there was
still no evidence of a dose-response for either
hormone (test for trend: progesterone p = 0.57;
estradiol p = 0.25). No signiﬁcant interaction
was found between menarche status at expo-
sure and TCDD for progesterone (p = 0.23) or
estradiol (p = 0.96).
The results did not change when women
who reported cessation of oral contraceptives
in the preceding 12 months (n = 11 in ovula-
tion models, n = 4 in progesterone and estra-
diol models) were excluded (data not shown). 
Discussion
To our knowledge, this is the ﬁrst epidemio-
logic study to examine the relation of individ-
ual serum TCDD levels and quality of ovarian
function in a highly exposed population. The
results of this study of women residing in
Seveso, Italy, in 1976 at the time of an explo-
sion, which released high levels of TCDD,
provide no clear evidence of an association of
exposure with quality of ovarian function
approximately 20 years later. TCDD levels
measured in serum collected near the time of
exposure were not associated with number or
size of ultrasound-detected ovarian follicles,
ovulation status, or serum hormone levels at
follow-up. 
This study also has several limitations that
should be considered. Although an association
between TCDD and ovarian function is bio-
logically plausible based on animal evidence, it
is possible that the women included in the
current study were not exposed during a criti-
cal period of development. In most of the
above-described animal studies, animals were
exposed prenatally whereas SWHS women
were exposed postnatally. Another limitation
is that we did not measure FSH and therefore
we were not able to examine the role of
TCDD on ovarian reserve. However, we pre-
viously reported a nonmonotonic dose-related
association with increasing risk of earlier
menopause up to about 100 ppt TCDD, but
not above, among women in SWHS—
suggesting the possibility of a relation of
TCDD on ovarian reserve.
In addition, phase of cycle may have been
misclassiﬁed for some women because the day
of cycle was based on self-report of menstrual
cycle length and date of last menstrual period.
We were able to collect only one serum hor-
mone measure during the menstrual cycle and
may have missed an effect of TCDD by meas-
uring over too wide a range in the menstrual
cycle, as evidenced by the somewhat stronger
finding of decrease in hormone levels when
the analysis was limited to women in the mid-
luteal phase. However, this study did measure
serum hormone levels directly, rather than
measuring urinary metabolites, which may
vary by woman depending on intrinsic and
extrinsic factors (Windham et al. 2002).
Another limitation of the study is that the
lowest exposure group (≤ 20.0 ppt) had rela-
tively high serum TCDD levels compared with
the contemporary levels we have reported for
this area (~ 2 ppt) (Warner et al. 2004). Also,
although the explosion resulted in exposure
speciﬁcally to TCDD, pooled serum samples
collected in 1976 from females who resided in
the unexposed area showed substantial back-
ground dioxin toxic equivalents (TEQ) expo-
sure (average = 100.4 ppt total TEQ, with
TCDD contributing 20.2 ppt TEQ and ana-
lytes other than TCDD contributing 80.2 ppt
TEQ) during this time period (Eskenazi et al.
2004). Therefore, SWHS participants with
TCDD levels < 20 ppt might still have had
substantial total TEQ exposure. Because we
measured only TCDD in this study due to the
small sample volume available (0.65 grams),
our results may underestimate an effect due to
dioxin TEQ exposure. However, an important
advantage of this study is that we were able to
measure TCDD levels in individual serum
samples collected near the time of exposure,
and there was a wide range of exposure. 
In summary, we found no clear evidence of
an association of TCDD exposure measured in
serum collected near the explosion on quality
of ovarian function 20 years later, including
ovarian follicles, ovulation status, and serum
hormones. The women in this study experi-
enced substantial TCDD exposure during the
postnatal developmental period. Animal evi-
dence suggests that in utero and lactational
TCDD exposure may have more significant
effects on ovarian function (Benedict et al.
2000; Heimler et al. 1998); therefore, contin-
ued follow-up of the younger women in the
SWHS cohort as well as the female offspring of
the SWHS cohort is essential. 
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